![PDF) Budesonide is superior to mesalazine in maintaining disease remission for patients with steroid-dependent Crohn's disease | Gerassimos Mantzaris - Academia.edu PDF) Budesonide is superior to mesalazine in maintaining disease remission for patients with steroid-dependent Crohn's disease | Gerassimos Mantzaris - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/56308898/mini_magick20190112-12781-aj6ct9.png?1547324961)
PDF) Budesonide is superior to mesalazine in maintaining disease remission for patients with steroid-dependent Crohn's disease | Gerassimos Mantzaris - Academia.edu
![John TRIANTAFILLIDIS | Inflammatory Bowel Disease Unit, IASO General Hospital, Athens, Greece | Associate Professor, University of Medicine and Pharmacy, Iasi, Romania | IASO Hospital, Athens, Athens | IASO | IBD unit John TRIANTAFILLIDIS | Inflammatory Bowel Disease Unit, IASO General Hospital, Athens, Greece | Associate Professor, University of Medicine and Pharmacy, Iasi, Romania | IASO Hospital, Athens, Athens | IASO | IBD unit](https://i1.rgstatic.net/ii/profile.image/1025633270386690-1621541435862_Q128/Gerassimos-Mantzaris.jpg)
John TRIANTAFILLIDIS | Inflammatory Bowel Disease Unit, IASO General Hospital, Athens, Greece | Associate Professor, University of Medicine and Pharmacy, Iasi, Romania | IASO Hospital, Athens, Athens | IASO | IBD unit
![PDF) P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study PDF) P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study](https://i1.rgstatic.net/publication/330639615_P621_Real-world_effectiveness_and_safety_of_vedolizumab_and_anti-TNF_in_biologic-naive_Crohn's_disease_patients_results_from_the_EVOLVE_study/links/606e1dd34585150fe98fe4a5/largepreview.png)
PDF) P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Resul
![PDF) Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease PDF) Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease](https://i1.rgstatic.net/publication/288888762_Prevalence_and_Characteristics_of_Extra-intestinal_Manifestations_in_a_Large_Cohort_of_Greek_Patients_with_Inflammatory_Bowel_Disease/links/5699e6dd08ae748dfaff9c74/largepreview.png)
PDF) Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease
![Julien KIRCHGESNER | Professor (Associate) | MD, PhD | Hôpital Saint-Antoine (Hôpitaux Universitaires Est Parisien), Paris | Service d'Hépato-Gastro-Entérologie - Nutrition Julien KIRCHGESNER | Professor (Associate) | MD, PhD | Hôpital Saint-Antoine (Hôpitaux Universitaires Est Parisien), Paris | Service d'Hépato-Gastro-Entérologie - Nutrition](https://i1.rgstatic.net/ii/profile.image/1067677464420353-1631565552837_Q512/Julien-Kirchgesner-2.jpg)